Metrika članka

  • citati u SCindeksu: 0
  • citati u Google Scholaru:[=>]
  • posete u prethodnih 30 dana:0
  • preuzimanja u prethodnih 30 dana:0
članak: 1 od 1  
Zbornik radova Tehnološkog fakulteta, Leskovac
2005, br. 14, str. 282-295
jezik rada: srpski
vrsta rada: članak

Uticaj ferocena na aktivnost tripsina
Tehnološki fakultet, Banja Luka

Sažetak

Veliki broj prelaznih metala i njihovih kompleksa može uspješno inhibirati djelovanje nekih proteolitičkih enzima kao što je tripsin. Njihovo inhibitorno djelovanje zasniva se na direktnom vezanju za aktivno mjesto tripsina imitirajući pentakoordinatno prelazno stanje. Iz tog razloga izabran je ferocen, kao potencijalni inhibitor, jer spada u organometalne sendvič spojeve čiji ciklopentadienilni prstenovi imaju takvu pretpostavljenu geometriju. U radu je ispitivan uticaj ferocena na aktivnost tripsina sa BAPNA-om (N-α-benzoil-DL-arginin p-nitroanilid) kao supstratom kao i uticaj ferocena na rast Esherichia coli ATCC 25922. Utvrđeno je da ferocen smanjuje brzinu enzimske reakcije, a takođe i da inhibitorno djeluje na rast Esherichia coli.

Ključne reči

Reference

Abad-Zapatero, C., Goldman, R., Muchmore, S.W., Hutchins, C., Stewart, K., Navaza, J., Payne, C.D., Ray, T.L. (1996) Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: Implications for the design of antifungal agents. Protein Sci, 5(4): 640-52
Abad-Zapatero, C., Goldman, R., Muchmore, S.W., Hutchins, C., Oie, T., Stewart, K., Cutfield, S.M., Cutfield, J.F., Foundling, S.I., Ray, T.L. (1998) Structure of secreted aspartic proteinases from Candida. Implications for the design of antifungal agents. Adv Exp Med Biol, 436: 297-313
Beckett, R.P., Davidson, A.H., Drummond, A.H., Huxley, P., Whittaker, M. (1996) Recent advances in matrix metalloprotease inhibitor research. DDT, 1 16
Bernstein, P.R., Edwards, P.D., Williams, J.C. (1994) Inhibitors of human leukocyte elastase. Prog Med Chem, 31: 59-120
Borman, S. (1996) Ferrocene derivatives find use as chiral catalysts. Chem. Eng. News, 74 38-40
Boycott, R., Klenk, H.D., Ohuchi, M. (1994) Cell tropism of influenza virus mediated by hemagglutinin activation at the stage of virus entry. Virology, 203(2): 313-9
Carraher, C.E., Pittman, C.U., Sheats, J.E., Zeldin, M. (2004) Overview of organoiron polymers. u: Macromolecules containing metal and metal-like elements 2, New York, itd: Wiley
Carraher, C.E., Pittman, C.U. (2004) Organometallic compounds in biomedical applications. u: Macromolecules containing metal and metal-like elements 3, New York, itd: Wiley
Dagani, R. (2002) The bio side of organometallics. Chem. Eng. News, 80 23-29
Darke, P.L., Huff, J.R. (1994) HIV protease as an inhibitor target for the treatment of AIDS. Adv Pharmacol, 25: 399-454
Duffy, B., Schwietert, C., France, A., Mann, N., Culbertson, K., Harmon, B., McCue, J.P. (1998) Transition metals as protease inhibitors. Biol Trace Elem Res, 64(1-3): 197-213
Fath, M.A., Wu, X., Hileman, R.E., Linhardt, R.J., Kashem, M.A., Nelson, R.M., Wright, C.D., Abraham, W.M. (1998) Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J Biol Chem, 273(22): 13563-9
Ghosh, P., D'Cruz, O.J., Narla, R.K., Uckun, F.M. (2000) Apoptosis-inducing vanadocene compounds against human testicular cancer. Clin Cancer Res, 6(4): 1536-45
Gibson, W., Hall, M.R. (1997) Assemblin, an essential herpesvirus proteinase. Drug Des Discov, 15(1): 39-47
Gurumoorthi, P., Pugalenthi, M., Janardhanan, K. (2003) Nutritional potential of five accesions of a south Indian tribal pulse: II. investigations on total free phenolics, tannins, trypsin and chymotrypsin inhibitors, phytohaemagglutinins, and in vitro protein digestability. Tropical and Subtropical Agroecosystems, 1 153-158
Hugli, T.E. (1996) Protease inhibitors: Novel therapeutic application and development. Trends Biotechnol, 14(11): 409-12
Johnson, L.L., Dyer, R., Hupe, D.J. (1998) Matrix metalloproteases. Current Opinion in Chemical Biology, 2466-471
Kempf, D.J., Sham, H.L. (1996) HIV protease inhibitors. Curr Pharm Des, 2 225-246
Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Landro, J.A., Chambers, S.P., Markland, W., Lepre, C.A., O'Malley, E.T., Harbeson, S.L., Rice, C.M., Murcko, M.A., Caron, P.R., Thomson, J.A. (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell, 87(2): 343-55
Kukrić, Z.Z., Žabić, M.M., Materić, D. (2003) Diciklopentadienilni kompleks željeza kao inhibitor tripsina. Glasnik hemičara i tehnologa Republike Srpske, 44, 432-442
Leung, D., Abbenante, G., Fairlie, D.P. (2000) Protease inhibitors: Current status and future prospects. J Med Chem, 43(3): 305-41
Li, Z., Chen, X., Davidson, E., Zwang, O., Mendis, C., Ring, C.S., Roush, W.R., Fegley, G., Li, R., Rosenthal, P.J. (1994) Anti-malarial drug development using models of enzyme structure. Chem Biol, 1(1): 31-7
Love, R.A., Parge, H.E., Wickersham, J.A., Hostomsky, Z., Habuka, N., Moomaw, E.W., Adachi, T., Hostomska, Z. (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell, 87(2): 331-42
Padeste, C., Grabelnik, A., Hefti, J.J., Tiefenauer, L. (2000) Ferrocene-avidin conjugates for biochemical applications. Biosensors and Bioelectronics, 15: 431-438
Schwietert, C.W. (1997) Biological affects of Ti(IV), a serine protease inhibitor. u: Annual Meeting of the Association of North Bay Scientist (17th), Santa Rosa, C A
Seife, C. (1997) Blunting nature's Swiss army knife. Science, 277(5332): 1602-3
Selkoe, D.J. (1997) Alzheimer's disease: Genotypes, phenotypes, and treatments. Science, 275(5300): 630-1
Shieh, H.S., Kurumbail, R.G., Stevens, A.M., Stegeman, R.A., Sturman, E.J., Pak, J.Y., Wittwer, A.J., Palmier, M.O., Wiegand, R.C., Holwerda, B.C., Stallings, W.C. (1996) Three-dimensional structure of human cytomegalovirus protease. Nature, 383(6597): 279-82
Silva, A.M., Lee, A.Y., Gulnik, S.V., Maier, P., Collins, J., Bhat, T.N., Collins, P.J., Cachau, R.E., Luker, K.E., Gluzman, I.Y., Francis, S.E., Oksman, A., Goldberg, D.E., Erickson, J.W. (1996) Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc Natl Acad Sci USA, 93(19): 10034-9
Stubbs, M.T., Bode, W. (1993) A player of many parts: The spotlight falls on thrombin's structure. Thromb Res, 69(1): 1-58
Tanaka, R.D., Clark, J.M., Warne, R.L., Abraham, W.M., Moore, W.R. (1995) Mast cell tryptase: A new target for therapeutic intervention in asthma. Int Arch Allergy Immunol, 107(1-3): 408-9
Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286(5440): 735-41
West, M.L., Fairlie, D.P. (1995) Targeting HIV-1 protease: A test of drug-design methodologies. Trends Pharmacol Sci, 16(2): 67-75
Wlodawer, A., Erickson, J.W. (1993) Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem, 62: 543-85
Yan, S., Sameni, M., Sloane, B.F. (1998) Cathepsin B and human tumor progression. Biol Chem, 379(2): 113-23